The effectiveness of vancomycin in the treatment of ulcerative colitis refractory to standard and biological therapy in liver transplant recipients

Background. Ulcerative colitis (UC) is a chronic inflammatory bowel disease of unknown etiology. Up to 80% of patients with primary sclerosing cholangitis have concomitant inflammatory bowel disease. Liver transplantation is the only curative treatment for end-stage chronic diffuse liver diseases. Treatment of UC is challenging, especially in patients who underwent liver transplantation and receive immunosuppressive therapy. Microbiota plays an important role in the pathogenesis of UC, although data on the efficacy of antibiotics in the treatment of UC are limited. We describe the effect of oral vancomycin treatment in three liver transplant recipients with UC refractory to conventional and biological therapy. All three patients achieved clinical remission and mucosal healing with oral vancomycin orally. Oral vancomycin treatment was well tolerated and resulted in sustained clinical and endoscopic remission in all three patients.

Objective. To demonstrate the efficacy of oral vancomycin in the treatment of refractory ulcerative colitis in liver transplant recipients.

Material and methods. The article presents observations of three liver transplant recipients with ulcerative colitis refractory to standard and biological therapy, who received vancomycin orally for 6 months.

Results. Remission of refractory ulcerative colitis in liver recipients was achieved by taking vancomycin orally.

Conclusion. Oral vancomycin administration in some cases lead to clinical and endoscopic remission of ulcerative colitis in recipients in whom standard and biological therapy for UC have not been effective.

1. . Uko V, Thangada S, Radhakrishnan K. Liver disorders in inflammatory bowel disease. Gastroenterol Res Pract. 2012;2012:642923. PMID: 22474447 https://doi.org/10.1155/2012/642923

2. Kim YS, Hurley EH, Park Y, Ko S. Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD): a condition exemplifying the crosstalk of the gut-liver axis. Exp Mol Med. 2023;55(7):1380–1387. PMID: 37464092 https://doi.org/10.1038/s12276-023-01042-9

3. Singh S, Loftus EV Jr, Talwalkar JA. Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Am J Gastroenterol. 2013;108(9):1417–1425. PMID: 23896954 https://doi.org/10.1038/ajg.2013.163

4. Mouchli MA, Singh S, Boardman L, Bruining DH, Lightner AL, Rosen CB, et al. Natural history of established and de novo inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Inflamm Bowel Dis. 2018;24(5):1074–1081. PMID: 29522202 https://doi.org/10.1093/ibd/izx096

5. Ravikumar R, Tsochatzis E, Jose S, Allison M, Athale A, Creamer F, et al. Risk factors for recurrent primary sclerosing cholangitis after liver transplantation. J Hepatol. 2015;63(5):1139– 1146. PMID: 26186988 https://doi.org/10.1016/j.jhep.2015.07.005

6. Visseren T, Erler NS, Heimbach JK, Eaton JE, Selzner N, Gulamhusein A, et al. Inflammatory conditions play a role in recurrence of PSC after liver transplantation: an international multicentre study. JHEP Rep. 2022;4(12):100599. PMID: 36426376 https://doi.org/10.1016/j.jhepr.2022.100599eCollection2022Dec

7. Ivashkin VT, Shelygin YuA, Abdulganiyeva DI, Abdulkhakov RA, Alekseyeva OP, Achkasov SI, et al. Guidelines of the Russian gastroenterological association and Russian Association of Coloproctology on diagnostics and treatment of ulcerative colitis in adults. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;25(1):48–65. (In Russ.).

8. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on sclerosing cholangitis. J Hepatol. 2022;77(3):761–806. PMID: 35738507 https://doi.org/10.1016/j.jhep.2022.05.011

9. Carbone M, Penna A, Mazzarelli C, De Martin E, Villard C, Bergquist A, et al. Liver Transplantation for Primary Sclerosing Cholangitis (PSC) with or without Inflammatory Bowel Disease (IBD)-A European Society of Organ Transplantation (ESOT) consensus statement. Transpl Int. 2023;36:11729. PMID: 37841645 https://doi.org/10.3389/ti.2023.11729eCollection2023.

10. Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16(1):2–17. PMID: 34635919 https://doi.org/10.1093/eccojcc/jjab178

11. Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384– 413. PMID: 30840605 https://doi.org/10.14309/ajg.0000000000000152

12. Kannegieter NM, Hesselink DA, Dieterich M, Kraaijeveld R, Rowshani AT, Leenen PJ, et al. The Effect of tacrolimus and mycophenolic acid on CD14+ monocyte activation and function. PLoS One. 2017;12(1):e0170806. PMID: 28122021 https://doi.org/10.1371/journal.pone.0170806eCollection2017.

13. Gómez-Massa E, Talayero P, Utrero-Rico A, Laguna-Goya R, Andrés A, Mancebo E, et al. Number and function of circulatory helper innate lymphoid cells are unaffected by immunosuppressive drugs used in solid organ recipients – a single centre cohort study. Transpl Int. 2020;33(4):402–413. PMID: 31908055 https://doi.org/10.1111/tri.13567

14. Han JW, Joo DJ, Kim JH, Rha MS, Koh JY, Park HJ, et al. Early reduction of regulatory T cells is associated with acute rejection in liver transplantation under tacrolimus-based immunosuppression with basiliximab induction. Am J Transplant. 2020;20(8):2058–2069. PMID: 31965710 https://doi.org/10.1111/ajt.15789

15. Miroux C, Morales O, Ghazal K, Othman SB, de Launoit Y, Pancré V, et al. In vitro effects of cyclosporine A and tacrolimus on regulatory T-cell proliferation and function. Transplantation. 2012;94(2):123–131. PMID: 22743548 https://doi.org/10.1097/TP.0b013e3182590d8f

16. Garo LP, Ajay AK, Fujiwara M, Beynon V, Kuhn C, Gabriely G, et al. Smad7 controls immunoregulatory PDL2/1-PD1 signaling in intestinal inflammation and autoimmunity. Cell Rep. 2019;28(13):3353–3366.e5. PMID: 31553906 https://doi.org/10.1016/j.celrep.2019.07.065

17. Sannaa W, Almasry M, Peedikayil M, Grimshaw AA, Attamimi M, AlMutairdi A, et al. Effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis. Therap Adv Gastroenterol. 20259;18:17562848241312766. PMID: 39802627 https://doi.org/10.1177/17562848241312766eCollection 2025.

18. Arbabzada N, Dennett L, Meng G, Peerani F. The effectiveness of oral vancomycin on inflammatory bowel disease in patients with primary sclerosing cholangitis: a systematic review. Inflamm Bowel Dis. 2025;31(7):2027–2035. PMID: 39495039 https://doi.org/10.1093/ibd/izae257

19. Dickinson RJ, O'Connor HJ, Pinder I, Hamilton I, Johnston D, Axon AT. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut. 1985;26(12):1380–1384. PMID: 3910524 https://doi.org/10.1136/gut.26.12.1380

20. Bianchimano P, Iwanowski K, Smith EM, Cantor A, Leone P, Bongers G, et al. Oral vancomycin treatment suppresses gut trypsin activity and preserves intestinal barrier function during EAE. iScience. 2023;26(11):108143. PMID: 37915599 https://doi.org/10.1016/j.isci.2023.108143eCollection2023Nov17.

21. Ayers, TD, Leonard-Puppa E, Kader HA, Waddell J, Watkins RD, Blanchard SS, et al. Oral vancomycin as an adjuvant treatment in IBD. Crohn's Colitis 360. 2019;1(2):otz015. https://doi.org/10.1093/crocol/otz015

22. Lev-Tzion R, Ledder O, Shteyer E, Tan MLN, Uhlig HH, Turner D. Oral vancomycin and gentamicin for treatment of very early onset inflammatory bowel disease. Digestion. 2017;95(4):310– 313. PMID: 28564649 https://doi.org/10.1159/000475660

23. Kasai K, Igarashi N, Tada Y, Kani K, Takano S, Yanagibashi T, et al. Impact of vancomycin treatment and gut microbiota on bile acid metabolism and the development of non-alcoholic steatohepatitis in mice. Int J Mol Sci. 2023;24(4):4050. PMID: 36835461 https://doi.org/10.3390/ijms24044050

24. Heumann D, Barras C, Severin A, Glauser MP, Tomasz A. Gram-positive cell walls stimulate synthesis of tumor necrosis factor alpha and interleukin-6 by human monocytes. Infect Immun. 1994;62(7):2715–2721. PMID: 7516310 https://doi.org/10.1128/iai.62.7.2715-2721.1994